10 likes | 13 Vues
Encouraging clinical results across various metabolic, hematological and ophthalmic disorders have inspired research groups across the world to focus their efforts on the development of novel gene editing therapies. In fact, the gene therapy pipeline has evolved significantly over the past few years, with three products being approved in 2019 alone; namely Beperminogene perplasmid (AnGes), ZOLGENSMAu00ae (AveXis) and ZYNTEGLOu2122 (bluebird bio). Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials that are anticipated to enter the market over the next 5-10 years. <br><br>To order this 670 page report, which features 190 figures and 340 tables, please visit this - https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html<br>
E N D